Atossa Genetics (NASDAQ:ATOS) Sets New 1-Year Low – What’s Next?

Atossa Genetics Inc. (NASDAQ:ATOS) shares hit a new 52-week low on Monday . The company traded as low as $6.17 and last traded at $6.35, with a volume of 234983 shares trading hands. The stock had previously closed at $8.4750.

Analysts Set New Price Targets

Several research analysts recently issued reports on ATOS shares. Ascendiant Capital Markets upped their target price on shares of Atossa Genetics from $116.25 to $120.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Atossa Genetics in a research note on Wednesday, January 21st. Finally, Zacks Research cut Atossa Genetics from a “hold” rating to a “strong sell” rating in a report on Monday, October 13th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Atossa Genetics has an average rating of “Hold” and an average price target of $95.00.

Atossa Genetics Trading Down 29.2%

The stock has a market cap of $775.28 million, a PE ratio of -24.94 and a beta of 1.09. The business has a fifty day simple moving average of $10.34 and a two-hundred day simple moving average of $11.94.

Atossa Genetics (NASDAQ:ATOS) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($1.05) EPS for the quarter, meeting the consensus estimate of ($1.05). On average, research analysts predict that Atossa Genetics Inc. will post -0.22 earnings per share for the current year.

Institutional Investors Weigh In On Atossa Genetics

Several hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in shares of Atossa Genetics by 4.2% in the 3rd quarter. Vanguard Group Inc. now owns 6,078,844 shares of the company’s stock worth $5,270,000 after purchasing an additional 245,717 shares during the last quarter. Ameriprise Financial Inc. purchased a new position in Atossa Genetics in the second quarter worth about $2,468,000. Jane Street Group LLC bought a new position in shares of Atossa Genetics in the second quarter worth approximately $381,000. Qube Research & Technologies Ltd grew its holdings in shares of Atossa Genetics by 357.4% during the second quarter. Qube Research & Technologies Ltd now owns 416,374 shares of the company’s stock valued at $346,000 after buying an additional 325,340 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of Atossa Genetics during the second quarter valued at approximately $321,000. 12.74% of the stock is owned by institutional investors.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.